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Abstract
c-Myc is one of the major human proto-oncogenes and is often
associated with tumor aggression and poor clinical outcome. Para-
doxically, Myc was also reported as a suppressor of cell motility,
invasiveness, and metastasis. Among the direct targets of Myc are
many components of the protein synthesis machinery whose
induction results in an overall increase in protein synthesis that
empowers tumor cell growth. At present, it is largely unknown
whether beyond the global enhancement of protein synthesis, Myc
activation results in translation modulation of specific genes. Here,
we measured Myc-induced global changes in gene expression at
the transcription, translation, and protein levels and uncovered
extensive transcript-specific regulation of protein translation.
Particularly, we detected a broad coordination between regulation
of transcription and translation upon modulation of Myc activity
and showed the connection of these responses to mTOR signaling
to enhance oncogenic transformation and to the TGFb pathway to
modulate cell migration and invasiveness. Our results elucidate
novel facets of Myc-induced cellular responses and provide a more
comprehensive view of the consequences of its activation in cancer
cells.
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Introduction
c-Myc (here termed Myc) is a major oncogene—it is overexpressed
and/or activated in more than half of human cancers and is often
associated with tumor aggression and poor clinical outcome [1–7].
Myc activation enhances key processes that contribute to tumorige-
nesis, including cell proliferation and growth, persistent DNA repli-
cation, protein biogenesis, and angiogenesis [8–12]. Suppression of
Myc expression back to its physiological levels results in tumor
regression in a wide variety of cancers, including hematopoietic,
epithelial, and mesenchymal tumors [7,13–16]. Paradoxically,
notwithstanding its strong oncogenic role, Myc was recently indi-
cated as a suppressor of cancer metastasis [17]. This effect was
attributed to Myc-mediated repression of aV and b3 integrin subunits
that results in reduced cell adhesion to ECM ligands, thus attenuat-
ing cell motility and invasiveness.
Myc is a basic helix–loop–helix (bHLH) transcription factor that
forms a heterodimer with Max and binds to E-box sequences
(canonical consensus 50-CACGTG-30) near the promoter elements of
actively transcribed genes [18]. Many gene expression profiling
studies have identified hundreds of Myc target genes in a variety of
tumor cells [19–23]. Recently, it was suggested that oncogenic Myc
is an amplifier, rather than a specifier, of gene expression in cancer
cells. This conclusion was based on the observation that in tumor
cells expressing high levels of Myc, it amplifies the output of the
existing gene expression program rather than inducing the expres-
sion of a new set of genes [24–26]. In addition to regulation of tran-
scription initiation, Myc was also shown to stimulate transcription
elongation at certain genes [26–31]. Recently, Myc was reported to
also directly repress transcription initiation of specific target genes,
and it was suggested that this negative effect is mediated by
complex formation of Myc and MIZ1 in promoters of the repressed
genes [32].
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Given its pivotal role in tumorigenesis, Myc is one of the most
vastly studied human TFs, and the effect of its activation on cellular
transcriptomes was thoroughly examined. In this study, we set out
to elucidate novel facets of Myc-induced responses and explore the
effects of its activation on regulation of protein translation. Global
enhancement of protein biogenesis upon Myc activation is well
documented. Among the direct targets of Myc are many components
of the protein synthesis machinery, including translation initiation
and elongation factors, tRNA synthetases, and ribosomal proteins of
the small and large ribosome subunits [33,34]. The induction of
these target genes results in an overall increase in cellular protein
synthesis that empowers cell growth [35]. However, at present, it is
largely unknown whether beyond this global effect on protein
synthesis, Myc activation also results in translation modulation of
specific transcripts, and how such responses might relate to its
oncogenic and metastatic-repressive effects. There are several
preliminary and intriguing indications for transcription-independent
Myc effects on protein translation [36,37], yet to date such possible
functions of Myc have not been systematically explored.
Here, we applied, in parallel, RNA-seq and Ribo-seq (also known
as ribosome profiling [38,39]) analyses and uncovered an extensive
transcript-specific regulation of protein translation induced by Myc,
in addition to the induction of a wide transcriptional response
network. Interestingly, we demonstrate that for dozens of Myc-
responsive transcripts (both induced and repressed), protein transla-
tion is modulated in a coordinated manner to augment the effect
exerted on their transcription, indicating a mechanistic coupling
between the regulation of the transcriptional and translational
layers of gene expression upon Myc activation. This coordination
between the transcriptional and protein translation responses
reinforces Myc effects that on the one hand strongly enhance
cancer transformation while on the other hand suppress cell
motility and invasiveness.
Results
The effect of Myc activation on cancer-cell transcriptomes was
previously characterized by many studies. Here, we set out to
systematically delineate transcript-specific effects of Myc activation
on protein translation. To this goal, we performed, in parallel, RNA-
seq and Ribo-seq analyses on U2OS cells containing an inducible
Myc expression vector (U2OS-Mycind; [32]) that were induced or
mock-treated in duplicates for 36 h. We selected this relatively late
time point in order to obtain global snapshots of the Myc response
network that is probably mediated by multiple secondary regulators.
We confirmed that, at this time, Myc did not trigger phenotypic
cellular changes such as cell cycle arrest or cell death. We carried
out the experiment using independent duplicates. We readily
detected the expression of 8,553 genes in the combined RNA-seq
and Ribo-seq datasets (Tables EV1 and EV2) and observed high
correlation between the Myc-induced responses in the two repeats
(see Materials and Methods and Fig EV1A–C). We also observed
that the Myc response measured by Ribo-seq was highly correlated
with the response measured by RNA-seq (Fig EV1D), indicating, as
expected, that a large portion of the alterations in protein translation
upon Myc induction reflected corresponding changes in mRNA
levels of the encoding genes. Overall, we identified 724 and 616
genes that consistently responded to Myc induction in either the
RNA-seq or Ribo-seq datasets, respectively (Fig EV1E). A total of
368 genes overlapped these two sets; thus, the combined dataset
detected 972 unique genes that responded to Myc activation at
either the RNA- or the protein translation level (or both).
Next, we subjected the set of Myc-responsive genes to cluster
analysis. This analysis delineated two main regulatory patterns in
both the Myc-induced and repressed expression programs (Fig 1A;
Table EV2). The first pattern (cluster #1 up and down) includes
genes whose change in ribosome occupancy mirrored to a large
extent the change observed in their mRNA level. Thus, in response
to Myc activation, these genes were mainly regulated at the RNA
level (i.e., regulation of gene transcription or transcript stability).
The second pattern (cluster #2 up and down) includes genes whose
alteration in ribosome occupancy was in the same direction but
augmented compared to the change in their mRNA level. Interest-
ingly, this response pattern suggests that Myc induction activates
feedforward loops that couple the regulation of mRNA levels and
translation rates (Fig 1B). To further characterize these two Myc-
induced regulatory modes, we calculated changes in transcripts’
translation efficiency (TE) and compared them with alterations in
mRNA level (Fig 1C). Genes assigned to cluster #1 (up or down)
showed a significant change in mRNA level and only a negligible
change in their TE, while genes assigned to cluster #2 showed coor-
dinated changes in their mRNA level and TE. This observation
suggests that despite the fact that genes assigned to cluster #2
showed reduced alteration in mRNA levels compared to genes
assigned to cluster #1, at protein level they should show more simi-
lar response, as the difference in mRNA alteration should be
compensated by the changes in TE of genes assigned to cluster #2.
To examine this expectation, we carried out a proteomic analysis of
the same biological conditions that were probed by RNA-and Ribo-
seq. We performed the proteomic analysis using independent tripli-
cates. (Proteomic measurements were noisier than RNA-seq and
Ribo-seq ones and showed lower correlations between repeats
(Fig EV1F).) The combined datasets containing measurements of
the three techniques included 4,665 genes/proteins (Table EV3).
The proteomic results confirmed our expectation and demonstrated
that the difference in Myc-induced protein-level alterations between
genes assigned to clusters #1 and #2 was narrowed compared to
their difference in mRNA-level responses (Fig 1D and E).
To functionally characterize the biological programs that are
exerted by the Myc-induced network, we examined the enrichment
of the above gene clusters for Gene Ontology (GO) functional cate-
gories (Table 1). We found that among the genes induced upon Myc
activation, cluster #1 was significantly enriched for genes that func-
tion in ribosome biogenesis and for transcription factors. Cluster #2
was enriched for subunits of RNA polymerase II (RNAPII) and of
the ribosome. Interestingly, this result indicates that upon Myc acti-
vation, subunits of both the transcription and translation core
machineries (the RNA-PolII and ribosome complexes) are coordi-
nately induced at the layers of mRNA expression and translational
efficiency. Among the genes that were repressed upon Myc activa-
tion, cluster #1 was enriched for cytoskeleton genes while cluster #2
was strikingly enriched for adhesion and extra cellular matrix (ECM)
proteins. The repression of the network of ECM-receptor interactions
included numerous collagens, laminins, and integrin subunits
(Fig EV2). This extensive suppressive response coordinated too the
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regulation of both mRNA and translation levels. Taken together, the
Myc-induced response enhances tumorigenesis while the Myc-
repressed response reduces cell adhesion to the ECM thus attenuat-
ing cellular motility and invasiveness.
Our analysis discovered an intriguing coordination between the
regulation of mRNA level and TE for dozens of Myc-induced and
repressed genes (see examples in Fig 2A). We experimentally exam-
ined this coupling for selected candidate genes. Changes in RNA
A B
C D E
Figure 1. Regulatory patterns in the Myc response network.
A Two main regulatory patterns detected by cluster analysis for the Myc-induced (left) and Myc-repressed (right) genes. For each gene, changes in RNA-seq and Ribo-
seq levels were standardized to mean = 0 and SD = 1 prior to clustering, such that genes assigned to the same cluster share similar response patterns but might
differ in their response magnitude. (y-axis represents standardized levels.) Each cluster plot shows the mean standardized change in mRNA level and ribosome
occupancy calculated over all the genes assigned to it (error bars equal SD calculated over the genes assigned to each cluster). Cluster #1 (for both induced and
repressed genes) contains genes that showed similar change in mRNA level and ribosome occupancy; cluster #2 contains genes whose change in ribosome
occupancy was in the same direction but amplified compared to the mRNA response.
B Cluster #2 (for both induced and repressed genes) indicates feedforward loops by which the response in mRNA level is further augmented by a coupled modulation
of protein translation. Myc-mediated effects could be direct or indirect.
C Distribution of alterations (log2 scale) in mRNA levels (left) and translation efficiencies (TE) (right) of genes assigned to the clusters shown in (A) (distribution of all
other genes in the dataset (“Bg”) is shown as well in light blue). Consistent with the pattern shown in (A), genes assigned to cluster #1 responded at mRNA level with
no or only marginal change in TE, while genes assigned to cluster #2 showed coordinated change in mRNA level and TE.
D Distribution of changes (log2 scale) in protein levels as measured by proteomic analysis for proteins encoded by the genes assigned to the clusters shown in (A). These
results confirm that differences in protein response between clusters #1 and #2 are narrowed compared to their differences in mRNA response (C, left) as these
differences are compensated by changes in TE (C, right).
E We compared changes in protein levels (DP; measured by proteomics) with changes in RNA levels (DR; measured by RNA-seq) in response to Myc induction for the
genes assigned to the four clusters shown in Fig 1A. As expected by the Ribo-seq results, while no significant difference was observed for genes assigned to cluster #1
(for which the change in protein level is accounted for by a corresponding change in RNA level), change in protein levels significantly differed from change in RNA
levels for genes assigned to clusters #2, as these genes are also subjected to modulation of translation efficiency upon Myc activation. P-values were calculated using
Wilcoxon’s test (comparing each distribution to the background one).
Data information: RNA-seq and Ribo-seq experiments were carried out using independent duplicate samples; proteomic analysis was carried out using independent
triplicates. For (C–E), in each boxplot, the box indicates the 1st and 3rd quartiles; the horizontal band inside the box indicates the median. The whiskers extend to the
most extreme data point which is no more than 1.5-times the interquartile range from the box.
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level were measured using RT–PCR and alterations in TE were
tested using polysome fractionation assay followed by RT–PCR to
quantify, for each transcript, relative portion in each fraction. From
the set of Myc-induced genes, we selected, for examination, two
subunits of RNAPII and its associated factor TAF1. These three
genes showed a clear transcript shift from lower to higher polysome-
associated fractions upon Myc activation, confirming the increase in
their TE (Fig 2B, left). From the set of Myc-repressed genes, we
selected three ECM proteins, all of them showed a transcript shift
from higher to lower polysome-associated fractions upon Myc activa-
tion, consistent with reduced TE (Fig 2B, right). These experimental
validations confirm that Myc activation results in transcript-specific
modulation of protein translation which is coupled to and augments
the Myc-induced program that regulates mRNA levels.
Factors that could potentially couple regulation of mRNA level
and protein translation are microRNAs (miRs) and RNA-binding
proteins (RBPs). Binding of miRs and RBPs to 30UTRs can modulate
both transcript stability and translation rate [40]. Alternatively, a
mechanism that couples the regulation of transcription rate and
translation efficiency is more puzzling, yet preliminary evidences
suggest that Myc could play such a role [37]. We therefore asked
whether, for genes that showed a coordinated change in mRNA
level and TE, the change in mRNA level was correlated with alter-
ations in transcription rate. Alternatively, changes in mRNA levels
of these genes could possibly be mainly due to modulation of their
transcript stability. RNA-seq measures steady-state expression levels
and consequently does not distinguish between changes in expres-
sion levels that stem from regulation of gene transcription or tran-
script stability. We therefore used global run-on coupled with
sequencing (GRO-seq) analysis, which measures the expression of
nascent transcripts and thus provides more direct estimates of gene
transcription rates [41]. We applied GRO-seq analysis, in biologi-
cally independent duplicates, to Myc-induced and control cells
(Table EV4; Fig EV3A). These data clearly demonstrated that
changes in mRNA levels (RNA-seq data) were correlated with
changes in transcription rates (GRO-seq data) also for genes whose
TE was modulated (that is, genes assigned to cluster #2) (Figs 3 and
EV3B), indicating that genes that showed a coordinated change in
mRNA level and TE were both transcriptionally and translationally
regulated in response to Myc activation.
We next examined which of the four regulatory patterns delin-
eated by clustering analysis in our dataset were likely to be
controlled directly by Myc binding to target gene promoters. We
analyzed a Myc ChIP-seq dataset that was recorded in the same
U2OS cellular system that was used in our experiments [32] and
tested intersections between Myc direct target genes defined by
ChIP-seq and our gene clusters. We sorted the putative Myc target
genes detected by ChIP-seq according to the strength of Myc binding
(binding affinity) to their promoters and found, as expected, that
the cluster containing genes that were transcriptionally induced
upon Myc activation (up cluster #1) was significantly enriched for
high-affinity Myc target genes (Table 2). The cluster of genes that
were coordinately induced at the layers of transcription and transla-
tion was enriched too, albeit to a lesser extent, for high-affinity Myc
target genes. On the other hand, the clusters containing genes
repressed upon Myc activation (cluster down #1 and #2) were
significantly depleted of high-affinity Myc targets (Table 2),
indicating either secondary effects to Myc activation or effects
specifically mediated by weak Myc binding. In line with previous
reports and using MIZ1 ChIP-seq data [32], we observed a statistical
overrepresentation of putative MIZ1 targets among the repressed
genes compared to the induced ones (33% vs. 26%, P = 0.04; chi-
squared test). In addition, computational motif analysis using iRegu-
lon [42] detected that the promoters of genes assigned to cluster
down #1 were significantly enriched for the binding motif of SP1
(P < 0.005; based on normal approximation for the enrichment
scores). Interestingly, a previous report indicated that Myc activa-
tion suppresses the expression of CDKN1A (p21) by sequestering
SP1 from the promoter of this gene (without direct binding of Myc
to this promoter) [43]. Seeking regulators of the Myc-induced trans-
lation modulation, we searched for enriched sequence motifs in the
50UTR and 30UTR of genes assigned to cluster up/down #2, but we
did not detect any, which may indicate a multifactorial mode of
translation regulation.
The clustering analysis described above was applied to the set of
972 genes that responded to Myc activation beyond certain cutoff
values. To further functionally characterize the Myc response, we
applied gene-set enrichment analysis (GSEA) [44], which does not
rely on any pre-set cutoff levels, but instead is based on ranks of all
genes detected in the data. For this analysis, we ranked the genes
Table 1. Functional enrichments in gene clusters.
Term Count P-value FDR Fold Enrichment
up1 GO:0042254 - ribosome biogenesis 18 8.7E-07 1.4E-03 4.2
GO:0006364 - rRNA processing 15 3.1E-06 2.4E-03 4.6
GO:0043565 - sequence-specific DNA binding 25 1.9E-05 8.8E-03 2.6
up2 GO:0033279 - ribosomal subunit 6 1.2E-03 1.9E-02 7.5
GO:0016591 - DNA-directed RNA polymerase II 5 1.6E-03 2.1E-02 9.9
down1 GO:0005856 - cytoskeleton 45 5.1E-06 1.5E-03 2.0
Steroid biosynthesis 7 2.5E-05 4.1E-03 11.8
lipid synthesis 8 6.3E-04 3.4E-02 5.5
down2 GO:0007155 - cell adhesion 49 8.5E-17 1.9E-13 4.0
GO:0031012 - extracellular matrix 28 7.8E-09 5.7E-07 3.7
GO:0034329 - cell junction assembly 9 4.2E-07 2.3E-04 12.6
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Figure 2. Validation of Myc-induced transcript-specific modulation of translation efficiency.
A Examples of genes that showed in the combined RNA- and Ribo-seq analysis modulation of TE upon Myc activation. (RNA-seq and Ribo-seq experiments were carried
out using independent duplicate samples).
B We selected for validation three candidate genes that showed increased (left) and decreased (right) TE, respectively. Changes in RNA level were measured using
RT–PCR, and alterations in TE were tested using polysome fractionation assay followed by RT–PCR to quantify, for each transcript, relative portion in each fraction.
Experiments were done in independent triplicates; error bars represent SD.
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twice: first, by their change in mRNA levels upon Myc induction,
and second, by the change in their TE in response to this treatment.
Reassuringly, GSEA results showed that the set of genes whose
mRNA level was up-regulated in response to Myc was enriched for
genes that were identified as Myc-induced targets by previous
transcriptomic studies (in other cellular systems) (Fig EV3C). With
respect to genes regulated at the layer of protein translation, GSEA
detected that the genes whose TE was elevated upon Myc induction
were strongly enriched for ribosomal protein (RP) genes (Fig 4A).
Individually, most RP genes showed only a modest increase in TE.
Yet, as a set, this group of genes, encoding for ribosome constituents
of both the large and small subunits, showed highly significant and
coordinated elevation in TE. This result reflects one of the well-
characterized oncogenic effects of Myc induction, namely global
enhancement of protein synthesis [45]. Several Ribo-seq studies
previously showed that global increase in TE of RP genes is a
molecular hallmark of mTOR activation [39,46]. This observation
therefore suggests that the mTOR pathway mediates some of the
translation modulation effects induced by Myc.
To explore this aspect, we repeated the Ribo-seq and RNA-seq
experiments in the presence of Torin-1, a potent inhibitor of mTOR
[47]. We found that the translational induction of RP genes upon
Myc activation was significantly abolished by Torin-1, indicating
that this response was largely mediated through a Myc-mTOR
signaling axis (Figs 4B and EV4A). In contrast, other components of
the Myc-induced transcriptional and translational responses were
not significantly affected by Torin-1 (Figs 4C and EV4B and C), indi-
cating that their regulation is not linked to the mTOR pathway.
Importantly, the extensive Myc-mediated translation repression of
the network of ECM and adhesion proteins was not compromised
by Torin-1 treatment, showing that mTOR pathway is not involved
in the regulation of this effect (Fig 4D). We further controlled
whether Torin-1 treatment affects Myc translation, as it was previ-
ously observed in another cellular system that mTOR inhibition
using rapamycin resulted in a reduction in the amount of Myc
mRNA associated with polysomes while total cellular Myc mRNA
level and MYC protein stability remained unchanged [48]. Using a
polysome fractionation assay, we find that in our system Torin-1 did
not affect Myc translation (Fig EV4D). Overall, our results indicate
that mTOR inhibition by Torin-1 specifically represses the myc-
mediated translational induction of ribosomal proteins while having
no marked effect on other parts of the Myc response network.
GSEA analysis also showed that the set of genes whose mRNA
level was down-regulated in response to Myc activation was
enriched for a gene signature that is up-regulated in invasive breast
cancer and that the set of genes whose TE was attenuated upon Myc
induction was strongly enriched for ECM and adhesion genes
(Fig 5A). This observation suggests that the link between the Myc
signaling pathway and cellular motility and invasiveness is wider
than appreciated so far, and that it is mediated by Myc modulation
of both gene transcription and protein translation. To further char-
acterize possible functional links between Myc activity and cancer
metastasis, we examined transcriptional and translational responses
to TGFb, a potent inducer of cell motility and invasiveness. Impor-
tantly, it was previously reported that TGFb inhibits Myc expression
[49]. We therefore examined the effect of TGFb treatment on the
transcriptome of the human mammary epithelial MCF10A cells,
a cellular system whose motility and invasiveness are strongly
enhanced by this treatment [50]. We probed the transcriptional
responses to TGFb at three time points (12 h, 24 h, and 48 h) and
in accord with previous reports, confirmed that it resulted in a
strong suppression of Myc expression (Fig 5B). Overall, we detected
more than 1,600 genes that were induced or repressed upon TGFb
treatment (Fig EV5). Cluster analysis delineated two major response
patterns containing the genes that were induced or repressed upon
TGFb treatment (Fig 5C). Concomitantly to Myc repression, the
cluster of down-regulated genes was significantly enriched for cell
Figure 3. Myc-induced changes in transcription rate.
Distribution of changes in transcription rates upon Myc activation measured by
GRO-seq for the set of genes assigned to the clusters shown in Fig 1A. GRO-seq
experiments were done using independent duplicate samples. For the boxplots,
the box indicates the 1st and 3rd quartiles; the horizontal band inside the box
indicates the median. The whiskers extend to the most extreme data point which
is no more than 1.5-times the interquartile range from the box.
Table 2. Enrichment and depletion of Myc direct target genes
(determined by ChIP-seq) in the main response clusters.
Cluster Top 1k*,† Top 2k Top 3k Top 4k
Down_1 7.46E-06 1.19E-06 1.06E-07 3.30E-08
Down_2 3.28E-05 4.88E-09 4.52E-12 2.22E-15
Up_1 1.84E-11 6.02E-11 9.33E-11 3.68E-08
Up_2 8.24E-05 0.00015 0.00011 0.0025
*P-values calculated using the tail of hypergeometric distribution. Negative
values indicate depletion of Myc direct target genes.
†Myc target genes were ranked according to the strength of Myc binding to
their promoter region. Intersections with genes assigned to the main
response clusters in our dataset were examined for the top 1k, 2k, 3k and 4k
Myc direct targets.
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cycle genes reflecting the anti-proliferative effect of TGFb. The
cluster of TGFb-induced genes was significantly enriched for adhe-
sion and ECM-protein encoding genes (Fig 5D), mirroring a reversed
effect to the one observed in response to Myc activation. As cell
invasion and migration depend on the interaction of the cell with
ligands in the ECM, these results suggest that Myc repression
contributes to the TGFb-mediated enhancement of cell motility and
invasiveness of MCF10A cells.
As we observed that both the oncogenic and metastasis-
repressive effects of Myc activation were carried out by coordinated
A
B C D
Figure 4. Effect of mTOR inhibition on the Myc-induced response.
A Right: GSEA analysis demonstrated that the genes whose TE was elevated uponMyc activation were significantly enriched for ribosomal proteins (RPs). Genes were sorted
from left to right according to the change in their TE in response to Myc induction. Vertical black bars indicate the location of RPs in this sorted list. (NES, normalized
enrichment score; p and q, nominal and multiple-testing corrected P-values, respectively.) Left: example of two RP genes whose TE is induced byMyc activation.
B Distribution of changes in TE measured for the set of RPs (of both the large and small ribosome subunits) in response to treatment with Torin-1, Myc, or Myc+Torin1.
The results show that Torin-1 treatment significantly attenuated the translation induction of the RP genes upon Myc activation.
C Distribution of changes in TE in response to Myc activation in the presence of Torin-1 measured for the set of genes assigned to the clusters shown in Fig 1A. Unlike
the drastic effect Torin-1 had on the translation induction of RP genes, much of the Myc-induced modulation of TE of genes assigned to these four clusters persisted
in the presence of Torin-1.
D Torin-1 did not compromise the strong translation repression of adhesion proteins upon Myc activation (shown are results for 51 genes functionally annotated as
encoding for adhesion proteins that were assigned to cluster down 2).
Data information: For the boxplots in (B–D), the box indicates the 1st and 3rd quartiles; the horizontal band inside the box indicates the median. The whiskers extend to
the most extreme data point which is no more than 1.5-times the interquartile range from the box.
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transcriptional and translational responses, we examined the effect
of TGFb on the efficiency of protein translation using Ribo-seq (48 h
post-TGFb treatment) (Table EV6). We found that reduction in Myc
activity due to TGFb treatment was accompanied by significant
increase in TE of adhesion genes and decrease in TE of ribosomal
protein genes, here too, mirroring a reversed effect to the one we
observed upon Myc activation (Fig 5E). To test the generality of our
observations, we examined transcriptional and translational
responses to TGFb treatment in a second cellular system, the
human-immortalized keratinocyte HaCat cells, whose motility and
invasiveness are enhanced by this treatment [51]. Applying a
combined RNA- and Ribo-seq analysis, we found that, in this
cellular system too, TGFb treatment resulted in a strong repression
of Myc expression (Fig 5F) that was accompanied by significant
repression of cell cycle genes and induction of adhesion and ECM
genes (Fig EV4B). Furthermore, in this cellular system too, TGFb
treatment resulted in increased TE of adhesion genes and attenuated
TE of RP genes (Fig 5G). Taken together, our results pinpoint key
A
C
D
E G
F
B
Figure 5. TGFb suppresses Myc-induced responses.
A GSEA analysis demonstrated that the genes repressed upon Myc activation were enriched for a gene signature that is up-regulated in invasive breast cancer (defined
by [61]), and that the genes whose TE was reduced upon Myc activation were enriched for genes encoding for adhesion and ECM proteins. (NES, normalized
enrichment score; p and q, nominal and multiple-testing corrected P-values, respectively.)
B Myc mRNA level in TGFb-treated MCF10A cells relative to its level in control sample as measured by RNA-seq.
C Main expression patterns detected in MCF10A in response to TGFb. Expression level of each gene was standardized to mean = 0 and SD = 1 prior to clustering.
y-axis shows standardized levels. Each cluster is represented by the average pattern calculate over all the genes it contains. Error bars represent  SD, calculated
over the genes assigned to each cluster.
D TGFb response of representative cell cycle and adhesion genes selected, respectively, from the repressed and induced gene clusters.
E TGFb treatment of MCF10A cells significantly increased TE of adhesion genes (left) and repressed TE of RP genes (right) (P-values were calculated using Wilcoxon’s test).
F Myc mRNA and translation levels in TGFb-treated HaCat cells relative to their levels in control HaCat sample as measured by RNA-seq and Ribo-seq.
G TGFb treatment of HaCat cells also significantly increased the TE of adhesion genes (left) and repressed the TE of RP genes (right). P-values were calculated using
Wilcoxon’s test.
Data information: For the boxplots in (E, G), the box indicates the 1st and 3rd quartiles; the horizontal band inside the box indicates the median. The whiskers extend to
the most extreme data point which is no more than 1.5-times the interquartile range from the box.
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roles of Myc in controlling oncogenesis and metastasis through
modulation of gene transcription and translation and indicate its
importance within the TGFb response network.
Discussion
In this study, we systematically explored the effect of Myc activation
on gene expression at the layers of transcription and protein transla-
tion. We unraveled that in addition to its known extensive effect on
the cellular transcriptome, Myc induction also results in a broad
transcript-specific modulation of protein synthesis. Remarkably, we
observed a widespread coordination between changes in RNA levels
and protein translation efficiencies. Profiling of nascent-RNA using
GRO-seq indicated that this effect results from a coupling between
transcription and translation efficiencies that is exerted by Myc to
enforce various cellular responses.
We found that the transcriptional response of dozens of Myc-
responsive genes is further amplified by a coupled translation
response. This effect was observed for both induced and repressed
genes. Such wide-scale coordination between the regulation of
gene transcription and protein translation is mechanistically
puzzling, and detailed experimental follow-up is required for its
elucidation. Yet, an intriguing report has already indicated tran-
scription-independent function of c-Myc in regulation of protein
translation [36]. Unexpectedly, it was shown that protein levels of
several cyclin-dependent kinases (CDKs) increased in response to
Myc induction without any change in their mRNA levels. Mecha-
nistically, it was demonstrated that Myc increases the translation
of these specific mRNAs by promoting the methylation of their 50
end (“cap methylation”) which is required for efficient translation.
This model could explain the coupling we observed between the
transcriptional and translational responses: Myc binding to
promoters enhances gene transcription and then further, for a
subset of transcripts, Myc enhances mRNA capping of the nascent
transcripts, thereby increasing their translation efficiency. For tran-
scripts that show an induction only in protein translation without
a change in mRNA levels, it was suggested that Myc enhances
mRNA capping without binding to the promoters thus functioning
in these cases as transcription-independent factor [37]. Similar
coupling between regulation of transcription and mRNA capping
carried out by other factors could potentially explain the coordi-
nated effect we observed for genes that were repressed upon Myc
activation. Further studies are required to elucidate the mecha-
nisms by which Myc activation modulates transcript-specific
protein translation, and whether these effects are directly regulated
by Myc (in a transcription-independent mode) or are secondary to
its activation and mediated by Myc-responsive regulators (e.g.,
RBPs, miRs).
From a functional perspective, our results further substantiate
that Myc activation concomitantly enhances cell growth and
oncogenic transformation while repressing cell migration and inva-
siveness. Interestingly, we demonstrate that both effects are
enforced by coordinated transcriptional and translational responses
(Fig 6). With respect to the oncogenic response arm, Myc activation
results in a broad induction of both the transcriptional (RNAPII) and
protein translation machineries. The induction of the translation of
the translation machinery itself is a molecular hallmark of mTOR
activation, and accordingly we show that mTOR inhibition by the
ATP-competitive Torin-1 inhibitor significantly attenuates this effect
of Myc. Importantly, mTOR-mediated global enhancement of
protein biogenesis is critical for Myc oncogenic function, and there-
fore, its inhibition was suggested as a strategy for treatment of Myc-
dependent human cancers. Significantly, a recent study uncovered a
functional link between Myc activation and mTOR-dependent phos-
phorylation of 4EBP1 protein [52], which is a key regulatory node of
protein translation. Furthermore, that study showed that the use of
another ATP-competitive mTOR inhibitor, MLN0128, which is
currently under clinical trials, attenuated 4EBP1 phosphorylation
and had a remarkable therapeutic efficacy in Myc-driven hematolog-
ical cancers. As differences in biological effect exerted by competi-
tive and allosteric mTOR inhibitors were documented in several
systems (e.g., [53]), it will be important to examine whether the
effect we observed for Torin-1 is elicited also by allosteric inhibition
of mTOR using rapamycin.
With respect to the metastasis-repressive response arm, Myc acti-
vation results in a global repression of an extensive network of ECM
and adhesion proteins that govern cell migration and invasiveness.
A recent study attributed Myc’s metastasis-repressive effect to its
transcriptional suppression of the aV and b3 integrin subunits [17].
We show that the repressive effect of Myc activation on cell interac-
tion with the ECM is in fact much broader and encompasses a coor-
dinated suppression of numerous ECM and adhesion proteins at
both the transcriptional and translational layers. As TGFb is a very
potent inducer of cell motility and invasiveness that was reported to
suppress Myc expression, we examined the effect of TGFb treatment
on gene expression and protein translation. Using two different
cellular systems, we confirmed that TGFb treatment strongly
decreased Myc levels and demonstrated that this suppression was
accompanied by transcriptional and translational responses reversed
to the ones observed upon Myc activation, including TE modulation
of ribosomal protein genes and of ECM and adhesion protein genes.
These results suggest that Myc suppression contributes to the
prometastatic function of the TGFb signaling pathway. However, it
is possible that this effect depends on cell-specific factors, as there
are cancer-cell models in which Myc was reported to enhance
TGFb-mediated epithelial-to-mesenchymal transition (EMT) [53].
Further increasing the complexity of the cross talk between Myc and
TGFb signaling is tumor-prompted stroma-derived signals. For
Figure 6. A schematic depiction of Myc-induced responses.
Myc coordinates extensive gene transcription and protein translation responses
to enhance cell transformation and suppress cell invasiveness and metastasis.
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example, induction of Myc in a transgenic mouse lymphoma model
stimulated surrounding macrophages to secrete TGFb, which
resulted in induction of cellular senescence [54].
Our current study reveals novel facets of the Myc-induced
network. Given its key role in tumorigenesis, therapies that target
Myc are under development. Our results highlight the challenge and
importance of developing novel therapeutic strategies specifically
aimed at blocking the oncogenic arm of the Myc signaling pathway
without affecting its metastasis-suppressive effects. Targeting the
mTOR pathway emerges as one such avenue that holds great
promise for treatment of cancers in which Myc activity is amplified
as we demonstrate that inhibition of mTOR strongly attenuates cell
growth effectors induced by Myc but has no effect on the extensive
Myc-mediated repression of the network of ECM and adhesion
proteins. Yet, as some components of the Myc-induced network are
cell-specific, the generalizability of our observations should be
examined by expanding our experiments to additional cancer-cell
models in which Myc activity is amplified.
Materials and Methods
Cell culture
Myc-inducible U2OS cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated fetal calf
serum in 5% CO2 at 37°C [32]. HaCat cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum.
MCF10A cells were cultured in DMEM/F12 1:1 medium supple-
mented with 5% horse serum, EGF (10 ng/ml), insulin (10 lg/ml),
cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5%
CO2 at 37°C. For TGFb1 treatment, MCF10a cells were treated with
human recombinant TGFb1 (10 ng/ml) for 48 h (R&D Systems);
HaCat cell were treated with TGFb1 (10 ng/ml) for 6 h.
RNA-seq
RNA-seq libraries were prepared using the TruSeq RNA Sample
Preparation Kit (Illumina) following the manufacturer’s instructions.
Samples were sequenced using Hi-Seq 2000 platform (single-end
reads; length of 50 nt).
Ribo-seq
Cells were treated with cycloheximide (100 lg/ml) for 5 min,
washed with ice-cold phosphate-buffered saline (cycloheximide,
100 lg/ml), pelleted, and lysed in buffer A (20 mM Tris–HCl, pH
7.8, 100 mM KCl, 10 mM MgCl2, 1% Triton X-100, 2 mM DTT,
100 lg/ml cycloheximide, and 1× complete protease inhibitor).
Lysates were centrifuged at 5,000 rpm, and the supernatant was
treated with 2 U/ll of RNase I (Ambion) for 40 min at room temper-
ature. Lysates were fractionated on a linear sucrose gradient (7 to
47%) using the SW-41Ti rotor at 36,000 rpm for 2 h. Fractions
enriched in monosomes were pooled and treated with proteinase K
(Roche) in a 1% SDS solution. Released RNA fragments were puri-
fied using TRIsure reagent and precipitated in the presence of
glycogen. For libraries preparation, RNA was gel-purified on a
denaturing 10% polyacrylamide urea (7 M) gel. A section
corresponding to 30 to 33 nucleotides, the region where most of
the ribosome-protected fragments are comprised, was excised,
eluted and ethanol precipitated. The resulting fragments were
30-dephosphorylated using T4 polynucleotide kinase (New England
BioLabs, Inc.) for 6 h at 37°C in 2-(N-morpholino) ethanesulfonic
acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2,
10 mM b-mercaptoethanol, and 300 mM NaCl). 30 adaptor was
added with T4 RNA ligase 1 (New England BioLabs, Inc.) for 2.5 h
at 37°C. Ligation products were 50-phosphorylated with T4
polynucleotide kinase for 30 min at 37°C. 50 adaptor was added
with T4 RNA ligase 1 for 18 h at 22°C. Libraries from HaCat cells
were sequenced in GAII and the MCF10a libraries in HiSeq 2000
(single-end reads; length of 50 nt).
GRO-seq
GRO-Seq protocol was performed as previously described with minor
modifications [41]. Briefly, cells were treated with doxycyline for 5 h
and 5 × 106 nuclei per condition were isolated and incubated 5 min
at 30°C with equal volume of reaction buffer for the nuclear run-on
(10 mM Tris–Cl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCl, 20
units of SUPERase In, 1% sarkosyl, 500 lM ATP, GTP, and Br-UTP,
0.2 lM CTP+32P CTP). The reaction was stopped and RNA extracted
with TRIzol LS (Invitrogen) according to the manufacturer’s instruc-
tions. Base hydrolysis was performed using RNA fragmentation
reagents (Ambion), and the reaction was purified through p-30
RNase-free spin column (Bio-Rad). BrUTP-labeled nascent tran-
scripts were immunoprecipitated with anti-BrUTP agarose beads
(Santa Cruz Biotech), washed once in binding buffer, once in
low-salt buffer (0.2× SSPE, 1 mM EDTA, 0.05% Tween-20), once in
high-salt buffer (0.25× SSPE, 1 mM EDTA, 0.05% Tween-20,
137.5 mM NaCl), and twice in TET buffer (TE with 0.05% Tween-
20). Then, BrUTP-incorporated RNA was eluted with elution buffer
(20 mM DTT, 300 mM NaCl, 5 mM Tris–Cl, pH 7.5, 1 mM EDTA,
and 0.1% SDS) and RNA isolated with TRIzol LS. End-repair of the
enriched BrUTP-incorporated RNAs was achieved by the treatment
with tobacco acid pyrophosphatase (TAP; Epicenter) to remove
50-methyl guanosine caps and followed by T4 polynucleotide kinase
treatment (PNK; NEB) to remove 30-phosphate group at low pH.
Then, the BrU-incorporated RNAs were treated with T4 PNK at high
pH in the presence of ATP to add 50-phosphate group. The reaction
was stopped, and RNA was extracted with TRIzol LS.
Library construction
Sequencing libraries were generated from two biological replicates
using TruSeq Small RNA kit from Illumina. Final libraries were
two times cleaned up and size-selected by Agencourt AMPure XP
(Beckman Coulter) and sequenced according to Illumina’s protocol
in a HiSeq 2000 platform.
Analysis of RNA-seq and Ribo-seq datasets
Sequenced reads were aligned to a reference set of human curated
protein-coding transcripts (plus the five human rRNA transcripts)
using bowtie [55]. This reference set of transcripts was based on
Ensembl gene annotations (release 65). Alignment statistics are
provided in Table EV1. For genes with multiple isoforms, the one
with longest coding DNA sequence (CDS) region and, in case not
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unique, the one with longest UTRs among the ones with the longest
CDS, was selected to represent the gene. Only uniquely mapped
reads were used in subsequent analyses. RNA expression levels and
ribosome occupancy were estimated by calculating reads per kilo-
base of mRNA per million reads (RPKM) per transcript, taking into
account either all reads that map to the transcript (for estimation of
RNA levels using RNA-seq data) or only those mapping to its CDS
(for estimation of ribosome occupancy). In estimation of ribosome
occupancy in CDS, 50 ends of reads were offset 12 nucleotides to the
30 direction to match the P-site location of ribosome [38]. RNA-seq
and Ribo-seq datasets were combined according to gene ID. Only
genes with at least 40 reads in at least one RNA-seq and one Ribo-
seq samples were included in subsequent analyses. The combined
Myc-U2OS dataset includes 8,553 (Table EV2). Fold change (FC) in
mRNA level and ribosome occupancy upon treatment were calcu-
lated per gene (in log2). To avoid inflation of FC estimates due to
low levels, RPKM levels below 1.0 were set to a “floor” value of 1.0.
Examination of relationship between gene response to Myc induc-
tion and transcript features showed a global association between
Ribo-seq FC estimates and transcript CDS length (Fig EV1A). We
normalized this technical effect using lowess normalization
(Fig EV1B).
Seeking genes that responded to Myc activation in either the
RNA-seq or Ribo-seq datasets, we set an adjusted fold-change
threshold that takes into account the higher measurement variability
among lowly expressed genes (Fig EV1E). We detected 724 genes
that consistently responded to Myc in the two RNA-seq experiments,
and 616 genes that consistently responded in the duplicate Ribo-seq
experiments. A total of 368 genes overlapped these two sets; thus,
972 unique genes were called responders in the combined dataset.
This set of genes was subjected to cluster analysis using the CLICK
algorithm implemented in the EXPANDER package [56]. Translation
efficiency (TE) was calculated for each gene per condition as the
(log2) ratio of its ribosome occupancy and RNA level. Functional
enrichment analysis was carried out using DAVID [57]. All other
statistical analyses were done in R.
Analysis of GRO-seq dataset
Sequenced reads were aligned to the human genome (hg19) using
bowtie 2, and a number of reads mapping to annotated genes
(Ensembl v69) were counted by HTseq [58]. Quantile normalization
was then applied to allow comparisons between different samples.
Only genes covered by at least 20 reads in at least one sample were
included in the analysis (Table EV4).
Analysis of Myc ChIP-seq dataset
We analyzed Myc ChIP-seq data from [32] that were measured on
the same U2OS system that we used in our RNA-, Ribo-, and
GRO-seq experiments. Fastq files were downloaded from GEO
(accession number GSE44672) and were aligned to the human
genome (hg19) using bowtie 2. We used Cisgenome [59] to detect
genomic binding sites bound by Myc. The comparison between Myc
and input samples detected 16,912 Myc binding sites at FDR cutoff
of 1%. For intersection with our dataset, Myc binding site was asso-
ciated with gene’s promoter if it was located within 5 kbp from
gene’s transcription start site (TSS).
Isolation of polysome-associated mRNA
Cells were lysed in buffer A containing 1 U of RNaseOUT (Invitro-
gen, Grand Island, NY, USA). Lysate was homogenized using a 26-G
needle, and the cytosolic extract was obtained by centrifugation at
1,300 g for 10 min. The extract was overlaid on a 7 to 47% linear
sucrose gradient and centrifuged in a SW41Ti rotor (Beckman Coul-
ter, California, USA) at 36,000 rpm for 2 h at 4°C. Fourteen fractions
were collected from the gradients, and RNA was isolated from each
using TRIsure reagent (Bioline). Reverse transcription was
performed using SuperScript III cDNA synthesis kit (Life Technolo-
gies) following the manufacturer’s instructions.
Real-time PCR
One microgram of total RNA was reverse transcribed using the
SuperScript III first-strand synthesis system (Life Technologies).
Real-time PCR was performed using the SensiFAST SYBR real-time
PCR kit (Bioline) in the LightCycler 480 System (Roche). Primers
used in this study are listed in Table EV5.
Proteomics analysis
Sample preparation and offline HpH-RP fractionation
Myc-induced and mock-treated U2OS cell lysates were sonicated in
lysis buffer (8 M urea in 50 mM ammonium bicarbonate (pH 8.5))
in the presence of protease inhibitors (Complete Mini tablets,
Roche) and subsequently cleared by centrifugation. Protein concen-
tration was determined with a 2D Quant Kit (GE Healthcare),
according to the manufacturer’s instructions. Aliquots correspond-
ing to 70 lg protein were first reduced with DTT and alkylated with
iodoacetamide, before proteolytic digestion with Lys-C (Wako) for
4 h at 37°C, enzyme/substrate ratio 1:75. The mixture was then
diluted fourfold to 2 M urea and digested overnight at 37°C with
sequencing grade trypsin (Promega) in enzyme/substrate ratio
1:100. Digestion was quenched by the addition of formic acid (final
concentration 10%), after which the peptides were simultaneously
desalted and stable isotope dimethyl labeled on a Sep-Pak C18
column (Waters, Massachusetts, USA). For 2 out of 3 biological repli-
cates, mock samples were labeled with “light” and Myc samples with
“heavy” label, whereas labels were swapped for the third replicate.
For each replicate, the light and heavy sample was mixed in a 1:1
ratio, dried down in a speed vacuum centrifuge, and stored at 80°C
until offline peptide fractionation. Basic reversed-phase (HpH-RP)
high-performance liquid chromatography separation of labeled
peptides was employed for offline peptide fractionation. Dried
peptides were reconstituted in 10 mM ammonium hydroxide
(NH4OH, solvent A) and loaded onto a Phenomenex Gemini C18
analytical column (100 mm × 1 mm, particle size 3 lm, 110 A˚
pores) coupled to an Agilent 1260 HPLC system consisting of a
nanopump, autosampler, multiple wavelength detector, and 96-well
plate fraction collector. Per replicate, 120 lg peptides were eluted at
a constant flow of 100 ll/min in a gradient containing a 30-min
linear increase from 0 to 10% solvent B (90% acetonitrile
(ACN)/10% NH4OH), a further increase to 23% solvent B at
t = 50 min, 30% solvent B at t = 61 min, and finally a 5-min wash
with 85% solvent B. A total number of 67 HpH-RP fractions were
collected, which were concatenated to 12 fractions and subsequently
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dried in a vacuum centrifuge. Prior to mass spectrometry analysis,
the peptides were reconstituted in 10% formic acid.
Mass spectrometry
Peptides were separated using the Proxeon nLC 1000 system
(Thermo Scientific, Bremen) fitted with a trapping (ReproSil-Pur 120
C18-AQ 3 lm (Dr. Maisch GmbH, Ammerbuch, Germany);
100 lm × 30 mm) and an analytical column (ReproSil-Pur 120 C18-
AQ 2.4 lm (Dr. Maisch GmbH); 75 lm × 500 mm), both packed in-
house. The outlet of the analytical column was coupled directly to a
Thermo Orbitrap Fusion hybrid mass spectrometer (Q-OT-qIT,
Thermo Scientific) using the Proxeon nanoflex source. Nanospray
was achieved using a distally coated fused silica tip emitter (gener-
ated in-house, o.d. 375 lm, i.d. 20 lm) operated at 2.1 kV. Solvent
A was 0.1% formic acid/water and solvent B was 0.1% formic acid/
ACN. Aliquots of concatenated HpH-RP fractions were eluted from
the analytical column at a constant flow of 250 nl/min in a 140-min
gradient, containing a 121-min linear increase from 7 to 25%
solvent B, followed by a 18-min wash at 80% solvent B. Survey
scans of peptide precursors from m/z 375–1,500 were performed at
120-K resolution with a 4 × 105 ion count target. Tandem MS was
performed by quadrupole isolation at 1.6 Th, followed by HCD frag-
mentation with normalized collision energy of 33 and ion trap MS2
fragment detection. The MS2 ion count target was set to 104, and the
max injection time was set to 50 ms. Only precursors with charge
state 2–6 were sampled for MS2. Monoisotopic precursor selection
was turned on; the dynamic exclusion duration was set to 30 s with
a 10 ppm tolerance around the selected precursor and its isotopes.
The instrument was run in top speed mode with 3-s cycles.
Data analysis
Raw data files were processed using Proteome Discoverer (PD,
version 1.4.1.14, Thermo Fisher Scientific). MS2 spectra were
searched against the Swissprot database (release 2014_08, 546,238
entries) using Mascot (version 2.5, Matrix Science, UK) and Homo
sapiens as taxonomy filter (20,194 entries). Carbamidomethylation
of cysteines was set as fixed modification and oxidation of methion-
ine; dimethyl “light” label (K and N-term) and dimethyl “heavy”
label (K and N-term) were set as a dynamic modifications. Trypsin
was specified as enzyme and up to two miscleavages were allowed.
Data filtering was performed using percolator, resulting in 1%
peptide false discovery rate (FDR), and Mascot peptide ion score
> 20 was set as additional filter. Protein [heavy/light] ratios were
log2-transformed and normalized on protein median.
Data availability
Raw sequence data of our study are deposited at GEO; accession
number GSE: GSE66929. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium [60] via the
PRIDE partner repository with the dataset identifier PXD002073.
Expanded View for this article is available online.
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